Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.
Kühne L, Knöbl P, Eller K, Thaler J, Sperr WR, Gleixner K, Osterholt T, Kaufeld J, Menne J, Buxhofer-Ausch V, Mühlfeld A, Seelow E, Schreiber A, Todorova P, Cukoski S, Jabs WJ, Özcan F, Gäckler A, Schönfelder K, Seibert FS, Westhoff T, Schwenger V, Eichenauer DA, Völker LA, Brinkkoetter PT. Kühne L, et al. Among authors: buxhofer ausch v. Blood. 2024 Oct 3;144(14):1486-1495. doi: 10.1182/blood.2023023780. Blood. 2024. PMID: 38838300
Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.
Kühne L, Kaufeld J, Völker LA, Wendt R, Schönermarck U, Hägele H, Osterholt T, Eichenauer DA, Bieringer M, von Bergwelt-Baildon A, Fischereder M, Buxhofer-Ausch V, Menne J, Brinkkoetter PT, Knöbl P. Kühne L, et al. J Thromb Haemost. 2022 Apr;20(4):951-960. doi: 10.1111/jth.15637. Epub 2022 Jan 23. J Thromb Haemost. 2022. PMID: 35000278 Free article.
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
Sperr WR, Herndlhofer S, Gleixner K, Girschikofsky M, Weltermann A, Machherndl-Spandl S, Sliwa T, Poehnl R, Buxhofer-Ausch V, Strecker K, Hoermann G, Knoebl P, Jaeger U, Geissler K, Kundi M, Valent P. Sperr WR, et al. Am J Hematol. 2017 Oct;92(10):E567-E574. doi: 10.1002/ajh.24847. Epub 2017 Aug 17. Am J Hematol. 2017. PMID: 28699225 Free PMC article. Clinical Trial.
A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study.
Petzer AL, Sperr WR, Buxhofer-Ausch V, Sliwa T, Schmidt S, Greil R, Wölfler A, Pichler P, Dormann C, Burgstaller S, Tinchon C, Lang A, Goebel F, Uthman S, Muenchmeier N, Valent P. Petzer AL, et al. Wien Klin Wochenschr. 2020 Aug;132(15-16):415-422. doi: 10.1007/s00508-020-01690-1. Epub 2020 Jun 12. Wien Klin Wochenschr. 2020. PMID: 32533444 Free PMC article.
Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
Worel N, Fritsch G, Agis H, Böhm A, Engelich G, Leitner GC, Geissler K, Gleixner K, Kalhs P, Buxhofer-Ausch V, Keil F, Kopetzky G, Mayr V, Rabitsch W, Reisner R, Rosskopf K, Ruckser R, Zoghlami C, Zojer N, Greinix HT. Worel N, et al. J Clin Apher. 2017 Aug;32(4):224-234. doi: 10.1002/jca.21496. Epub 2016 Aug 31. J Clin Apher. 2017. PMID: 27578390
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
Pecquet C, Papadopoulos N, Balligand T, Chachoua I, Tisserand A, Vertenoeil G, Nédélec A, Vertommen D, Roy A, Marty C, Nivarthi H, Defour JP, El-Khoury M, Hug E, Majoros A, Xu E, Zagrijtschuk O, Fertig TE, Marta DS, Gisslinger H, Gisslinger B, Schalling M, Casetti I, Rumi E, Pietra D, Cavalloni C, Arcaini L, Cazzola M, Komatsu N, Kihara Y, Sunami Y, Edahiro Y, Araki M, Lesyk R, Buxhofer-Ausch V, Heibl S, Pasquier F, Havelange V, Plo I, Vainchenker W, Kralovics R, Constantinescu SN. Pecquet C, et al. Blood. 2023 Feb 23;141(8):917-929. doi: 10.1182/blood.2022016846. Blood. 2023. PMID: 36356299 Free PMC article.
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Gisslinger H, et al. Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10. Blood. 2015. PMID: 26261238 Free PMC article. Clinical Trial.
75 results